-
Mashup Score: 2The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis - PubMed - 13 hour(s) ago
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal organ relapse is not clear.Methods: We present eight patients with AL amyloidosis who had a repeat kidney biopsy perfor …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5What Are the Benefits of Myeloma Consults and Second Opinions? - Patient Empowerment Network - 1 day(s) ago
What can myeloma consults and second opinions bring to patients? Dr. Ola Landgren shares his perspective on the benefits.
Source: powerfulpatients.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 26Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma - 2 day(s) ago
Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.Maintenance treatmen
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Plus, a bone-marrow-transplant revolution, and why fewer college football players are entering the NFL draft.
Source: apple.newsCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Program Guide – ASCO Meeting Program Guide - 4 day(s) ago
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Source: meetings.asco.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Program Guide – ASCO Meeting Program Guide - 4 day(s) ago
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Source: meetings.asco.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19Our Journey | Emily Whitehead Foundation - 11 day(s) ago
Emily Whitehead has been in remission since 2012 after receiving CAR T-cell therapy to treat her leukemia.
Source: emilywhiteheadfoundation.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter ed is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. This value is admissible, but you may wish to double check it. This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now. This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now. This
Source: redcap.iths.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 18
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physicians’ practice patterns for surveillance, diagnosis, and management of CAR-T failure.
Source: www.astctjournal.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies - Florida Hospital News and Healthcare Report - 14 day(s) ago
“Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of Sylvester’s Myeloma Research Institute. “It […]
Source: southfloridahospitalnews.comCategories: General Medicine News, Partners & KOLsTweet
RT @vsanchorawala: @Phhersh Agree with all comments! Our paper on utility of repeat kidney biopsy in this scenario. https://t.co/znxa11IVJS…